- Home
- MATH vs OTLK Comparison
MATH vs OTLK Comparison
Compare MATH & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- OTLK
- Stock Information
- Founded
- MATH 2015
- OTLK 2010
- Country
- MATH Hong Kong
- OTLK United States
- Employees
- MATH N/A
- OTLK N/A
- Industry
- MATH Finance/Investors Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MATH Finance
- OTLK Health Care
- Exchange
- MATH Nasdaq
- OTLK Nasdaq
- Market Cap
- MATH 64.9M
- OTLK 56.3M
- IPO Year
- MATH N/A
- OTLK 2016
- Fundamental
- Price
- MATH $1.70
- OTLK $1.22
- Analyst Decision
- MATH
- OTLK Strong Buy
- Analyst Count
- MATH 0
- OTLK 5
- Target Price
- MATH N/A
- OTLK $10.20
- AVG Volume (30 Days)
- MATH 105.6K
- OTLK 362.1K
- Earning Date
- MATH 10-31-2024
- OTLK 05-14-2025
- Dividend Yield
- MATH N/A
- OTLK N/A
- EPS Growth
- MATH N/A
- OTLK N/A
- EPS
- MATH 0.17
- OTLK N/A
- Revenue
- MATH $31,399,049.00
- OTLK N/A
- Revenue This Year
- MATH N/A
- OTLK N/A
- Revenue Next Year
- MATH N/A
- OTLK $288.46
- P/E Ratio
- MATH $10.35
- OTLK N/A
- Revenue Growth
- MATH 291.58
- OTLK N/A
- 52 Week Low
- MATH $0.80
- OTLK $0.87
- 52 Week High
- MATH $2.78
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- MATH 45.52
- OTLK 33.91
- Support Level
- MATH $1.70
- OTLK $1.25
- Resistance Level
- MATH $2.10
- OTLK $1.42
- Average True Range (ATR)
- MATH 0.14
- OTLK 0.11
- MACD
- MATH -0.02
- OTLK -0.01
- Stochastic Oscillator
- MATH 7.50
- OTLK 7.89
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.